COLEY PHARMACEUTICAL GROUP FILES REGISTRATION STATEMENT FOR PROPOSED
INITIAL PUBLIC OFFERING
WELLESLEY, MA - April 20, 2005
- Coley Pharmaceutical Group, Inc. today announced that the Company has filed a
registration statement with the U.S. Securities and Exchange Commission relating
to the proposed initial public offering of its common stock. All shares of the
common stock to be sold in the offering will be offered by the Company.
Merrill Lynch & Co. is sole book runner for the offering with J.P.
Morgan Securities Inc. acting as co-lead. Lazard and Leerink Swann &
Company are acting as co-managers for the offering.
A registration statement relating to these securities has been filed
with the Securities and Exchange Commission but has not yet become
effective. These securities may not be sold nor may offers to buy be
accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor will there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
When available, copies of the preliminary prospectus relating to the
offering may be obtained from: Merrill Lynch & Co., 4 World Financial
Center, New York, New York 10080 (telephone: +1.212.449.1000).
About Coley Pharmaceutical Group
Coley Pharmaceutical is an international biopharmaceutical company,
headquartered in Wellesley, Massachusetts, USA, that discovers and
develops TLR Therapeutics TM , a new class of investigational drug
candidates that direct the human immune system to treat cancers,
infectious diseases, asthma and allergy. Coley has established a
pipeline of four TLR Therapeutic product candidates currently advancing
through clinical development either independently or with partners, and
additional product candidates in preclinical development. Coley has
product development, research and license agreements with Pfizer,
sanofi-aventis, Chiron, the United States Government and